Redefining evidence for teprotumumab in thyroid eye disease: an updated meta-analysis of efficacy and safety
Teprotumumab provides substantial, consistent benefits in improving proptosis, diplopia, disease activity and GO-QOL in TED. Clinicians should monitor for adverse events, particularly hyperglycemia and hearing impairment. These findings reinforce teprotumumab as a pivotal therapeutic option and support balanced risk-benefit evaluation.
Authors
- Xiao Zhang (ORCID: https://orcid.org/0000-0003-1706-2868)
- Jing Guo (ORCID: https://orcid.org/0000-0002-6399-3877)
- Li Li Ji (ORCID: https://orcid.org/0000-0001-9579-6723)
- Xiuying Zhang (ORCID: https://orcid.org/0000-0002-2083-8105)
- Rongjing Song
- Xiaofang Niu
- Shasha Li
- Wei Zhao
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Heze Municipal Hospital (CN)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2026-02-13
- DOI
- https://doi.org/10.3389/fendo.2026.1735660
- Primary Topic
- Ophthalmology and Eye Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Peking University
- Peking University People's Hospital